MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Commentary
Five top tips for commercial space leasing for startups and SMEs
What makes SASE a key asset for banks in Hong Kong
Scoring an advertising touchdown: Super Bowl 2025 marketing lessons for Hong Kong events